In addition, SMYD2 inhibitor BAY-598 can significantly enhance the sensitivity of the doxorubicin against NSCLC, through coordinately inhibited the JAK-STAT signaling pathway [40]. The gene discussed is SMYD2; the disease is non-small cell lung carcinoma.